Progyny (NASDAQ:PGNY) Issues Q2 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its second quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.500-0.53 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $342.0 million-$355.0 million, compared to the consensus revenue estimate of $349.5 million. Progyny also updated its FY 2026 guidance to 1.980-2.09 EPS.

Analyst Ratings Changes

Several research firms have recently commented on PGNY. Citigroup upgraded shares of Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price for the company in a research note on Tuesday, January 20th. KeyCorp reduced their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Finally, BTIG Research reduced their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.91.

Progyny Stock Performance

NASDAQ:PGNY traded up $0.46 during mid-day trading on Thursday, hitting $19.16. 1,827,030 shares of the company’s stock traded hands, compared to its average volume of 1,499,703. The firm’s 50 day simple moving average is $17.91 and its 200 day simple moving average is $21.69. Progyny has a 1 year low of $16.10 and a 1 year high of $28.75. The company has a market cap of $1.50 billion, a PE ratio of 29.48, a price-to-earnings-growth ratio of 1.09 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.06. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, research analysts expect that Progyny will post 1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 7,455 shares of company stock worth $129,515. Company insiders own 9.90% of the company’s stock.

Institutional Investors Weigh In On Progyny

A number of hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp grew its holdings in shares of Progyny by 1.5% during the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after buying an additional 44,642 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after buying an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after buying an additional 545,431 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after buying an additional 20,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Progyny by 12.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock worth $43,966,000 after buying an additional 184,679 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.